Photo 1: Photo shows (from left to right) Ms Meng Yu, Ms Li Yu, Dr Leigh MacConell, Dr Xun Zhu, Dr Liping Liu, Mr Lixiong Ma, Mr Edmund Sim, Ms Liping Gao, and Mr Wenjun Fu attending the bell-ringing ceremony. (Hong Kong,

[source from:Global Business Reports ] Can you introduce HighTide Therapeutics and present key highlights from 2022? HighTide was founded in 2011. We are a globally integrated biotech company with operations in the US and China.

[ source from:Biopharma ] HighTide Therapeutics Inc. a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phas

[ source from：the Washington Business Journal ] Metabolic and digestive disease specialist HighTide Therapeutics has raised $107 million in a series C financing led by China’s TCM Healthcare Fund, with money also from Yuexiu Fund and Yuthai Fund.

[ source from：The pharma letter ] Metabolic and digestive disease specialist HighTide Therapeutics has raised S107 million in aseries C financing led by China's TCM Healthcare Fund, with money also from Yuexiu Fundand Yuthai Fund.

[ source from：Endpoints News ] HighTide Therapeutics has raised a $107 million Series C round to fund mid-stage studies in metabolic and digestive diseases, with the goal of filing for approval in China within two to three years.